JP2905911B2 - Agent for suppressing or increasing the number of helper T cells in AIDS - Google Patents
Agent for suppressing or increasing the number of helper T cells in AIDSInfo
- Publication number
- JP2905911B2 JP2905911B2 JP5218908A JP21890893A JP2905911B2 JP 2905911 B2 JP2905911 B2 JP 2905911B2 JP 5218908 A JP5218908 A JP 5218908A JP 21890893 A JP21890893 A JP 21890893A JP 2905911 B2 JP2905911 B2 JP 2905911B2
- Authority
- JP
- Japan
- Prior art keywords
- helper
- cells
- aids
- maitake
- suppressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明はAIDS(エイズ)にお
けるヘルパーT細胞(CD4陽性リンパ球〔以下CD4
と表す〕)数の減少抑制若しくは増加剤に関するもので
ある。This invention relates to AIDS (AIDS) .
Helper T cells (CD4-positive lymphocytes [hereinafter CD4
]) This relates to an agent for suppressing or increasing the decrease in the number .
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】AID
Sは、後天性免疫不全症候群と云われるように免疫が低
下するものである。即ち、ヘルパーT細胞がHIVのタ
ーゲット細胞である。このAIDSによる免疫の低下を
防止するため、本発明者等は、マイタケが有する免疫強
化作用に着目し、HIVの感染によって認められるヘル
パーT細胞数の減少を抑制若しくは増加させると共に、
関連症状の改善を行わせることを目的として種々実験を
繰り返した結果、本発明を完成した。2. Description of the Related Art AID
S is one in which immunity is reduced, which is called acquired immunodeficiency syndrome. That is, helper T cells are target cells for HIV. In order to prevent the reduction of immunity due to AIDS, the present inventors focused on the immunopotentiating effect of maitake, and suppressed or increased the decrease in the number of helper T cells observed by HIV infection,
As a result of repeating various experiments for the purpose of improving related symptoms, the present invention was completed.
【0003】この様なマイタケが有する免疫強化作用を
用いてAIDS症を改善する方法はいまだ行われておら
ず、この方法が我国において最初のものであり、世界で
も例がない。[0003] A method for improving AIDS disease by using the immunopotentiating action of maitake has not yet been performed, and this method is the first in Japan and has no examples in the world.
【0004】[0004]
【課題を解決するための手段】本発明の要旨を説明す
る。The gist of the present invention will be described.
【0005】AIDSにおけるヘルパーT細胞数の減少
抑制若しくは増加剤であって、マイタケの子実体若しく
は培養菌糸体を乾燥し、該乾燥物を粉末化して成る、投
与量が成人1日当たり3乃至10gであることを特徴と
するAIDSにおけるヘルパーT細胞数の減少抑制若し
くは増加剤に係るものである。[0005] Reduction of helper T cell numbers in AIDS
It is a suppressant or an enhancer, and the fruit body of Maitake is young
Is a method of drying cultured mycelium and pulverizing the dried product.
The dosage is 3 to 10 g per adult per day.
Suppression of helper T cell count in AIDS
Or an increaser .
【0006】AIDSにおけるヘルパーT細胞数の減少
抑制若しくは増加剤であって、マイタケの子実体若しく
は培養菌糸体を乾燥し、該乾燥物を粉末化して成る、投
与量が成人1日当たり3gであることを特徴とするAI
DSにおけるヘルパーT細胞数の減少抑制若しくは増加
剤に係るものである。[0006] Reduced number of helper T cells in AIDS
It is a suppressant or an enhancer, and the fruit body of Maitake is young
Is a method of drying cultured mycelium and pulverizing the dried product.
AI characterized in that the dosage is 3 g per adult per day
Suppression or increase of helper T cell count in DS
Pertaining to agents .
【0007】[0007]
【0008】[0008]
【0009】[0009]
【作用】マイタケ中のグルカンがヘルパーT細胞の減少
を抑制若しくは増加させる。The glucan in maitake suppresses or increases the decrease in helper T cells.
【0010】[0010]
【実施例】マイタケ(チョレイマイタケや白マイタケな
どGrifola属に属するものはすべて含まれる。)の子実
体(人口栽培および天然物のいずれでもよい。)若しく
は培養菌糸のいずれでもよいが、これらの乾燥物から得
た粉末を錠剤状にしたものまたは該乾燥物の熱水可溶物
をドリンク剤状にしたものを用いる。EXAMPLES The fruit body of maitake (including all those belonging to the genus Grifola, such as Choreimaitake and white maitake) may be any of artificially cultivated and natural products or cultured mycelium. The powder obtained from the dried product is made into a tablet, or the hot-water-soluble material of the dried product is made into a drink.
【0011】マイタケの乾燥粉末を低温下(4°C〜8
0°C)で打錠する。この時、各種のビタミンをマイタ
ケ特有の香りを緩和すると共に該粉末の酸化を防止する
ため、粉末100mg当たり1〜20mgの割合で混合
する。[0011] The dry powder of Grifola low temperature (4 ° C~8
Tablet at 0 ° C). At this time, various vitamins are mixed at a ratio of 1 to 20 mg per 100 mg of the powder in order to alleviate the fragrance peculiar to Maitake and prevent oxidation of the powder.
【0012】打錠せず、この混和物をカプセルにつめた
り、或いは、そのまま粉末状のものとしたりしても良
い。This tablet may be filled in a capsule without compression, or may be made into a powder form as it is.
【0013】尚、ビタミンを混和することは必ずしも必
要とするものではなく、無添加でも良い。It should be noted that it is not always necessary to mix vitamins, and they may not be added.
【0014】この粉末は1日当たり3g〜10g経口投
与する。This powder is orally administered in an amount of 3 g to 10 g per day.
【0015】また、生マイタケの子実体1kg若しくは
生マイタケの子実体の乾燥物200gに、水を2リット
ル若しくは800mlを加え、90°C〜140°Cの
加熱処理を行う。得られた抽出液そのまま、または抽出
液中に含まれる高分子多糖体をエキスとして経口投与に
用いる。Further, 2 liters or 800 ml of water is added to 1 kg of raw maitake fruit body or 200 g of dried raw maitake fruit body, and a heat treatment at 90 ° C. to 140 ° C. is performed. The obtained extract is used as it is, or the high molecular polysaccharide contained in the extract is used for oral administration as an extract.
【0016】尚、この多糖物は注射によって投与しても
良い。更に、このエキスを乾固し、乳糖などに混じ、錠
剤またはカプセルにつめて経口投与しても良い。The polysaccharide may be administered by injection. Further, the extract may be dried, mixed with lactose or the like, and packed in tablets or capsules for oral administration.
【0017】このエキスは糖量にして1日当たり10m
g〜200mg経口投与する。This extract has a sugar content of 10 m / day
g-200 mg orally.
【0018】AIDS患者に、前記マイタケの粉末を1
日3g経口投与し、2カ月後のヘルパーT細胞(CD
4)の数を調べたところ、増加または減少が抑えられる
ことが認められた。その結果の一部は次の表1である。For AIDS patients, the maitake powder was
3 g / day orally and 2 months later, helper T cells (CD
When the number of 4) was examined, it was found that the increase or decrease was suppressed. Some of the results are shown in Table 1 below.
【表1】 表2に、この時のヘルパーT細胞(CD4)数対サプレ
ッサーT細胞(CD8)数の比率の一部を示す。[Table 1] Table 2 shows a part of the ratio of the number of helper T cells (CD4) to the number of suppressor T cells (CD8) at this time.
【表2】 一般に健常者ではヘルパーT細胞(CD4)/サプレッ
サーT細胞(CD8)の比率は約2であるが、この表2
にも示すようにAIDS患者ではヘルパーT細胞(CD
4)の数が減少することにより、その比率も非常に小さ
くなっている。しかし、前記マイタケの粉末の投与によ
り、その比率が増加することが認められた。[Table 2] In general, the ratio of helper T cells (CD4) / suppressor T cells (CD8) is about 2 in healthy subjects.
As shown also in AIDS patients, helper T cells (CD
As the number of items 4) decreases, the ratio becomes very small. However, it was found that the administration of the maitake powder increased the ratio.
【0019】この結果は、HIV感染によって生ずるヘ
ルパーT細胞(CD4)の減少を、マイタケがその免疫
力の増強または回復作用によって抑制することを示すも
のである。These results indicate that Maitake mushroom suppresses the decrease in helper T cells (CD4) caused by HIV infection by enhancing or restoring its immunity.
【0020】これは、現在、治療に用いられているAZ
TやDDIがHIVの増殖に関する逆転写酵素の作用な
どを直接的に阻害し、症状改善或いは回復を行わせるも
のとは全く異なり、免疫力の改善、回復を行わせて治療
を行うというものである。This is because AZ is currently used for treatment.
T and DDI directly inhibit the action of reverse transcriptase on HIV growth, etc., and are completely different from those that improve or relieve symptoms. is there.
【0021】このような事実に基づいてAIDS症を軽
減しようという試みは我国においてのみならず世界的に
も初めてのものである。An attempt to reduce AIDS based on such facts is the first in Japan as well as in the world.
【0022】その結果HIVのターゲットであるヘルパ
ーT細胞(CD4)の回復のみならず、表3に示すよう
なAIDS関連症候をも軽減し得た。As a result, not only recovery of helper T cells (CD4) , which is a target of HIV, but also AIDS-related symptoms as shown in Table 3 could be reduced.
【表3】 以上の臨床試験結果は、マイタケの粉末を経口投与する
と、HIV陽性患者(AIDS患者及びAIDSキャリ
ヤーを含む。)の免疫力の回復が認められ、その結果と
してHIV感染にともなうAIDS関連症候症状が軽減
されることを示すものである。[Table 3] Clinical test results described above, when administered orally powder maitake, observed recovery of immunity HIV-positive patients (. Including AIDS patients and AIDS carriers), AIDS-related symptoms symptoms associated with HIV infection as a result It shows that it is reduced.
【0023】我国においてのみならず、世界的にもこの
ようなマイタケの製剤を用いたAIDSに対する一連の
臨床試験例はなく、これが初めてであり、かつ有効との
判定から、本発明は有意義なものと考える。尚、前記マ
イタケのエキス投与でも、同様の臨床試験結果が得られ
ている。[0023] Not only in Japan, worldwide is also not a series of clinical Test Example for AIDS using formulations such maitake, this is the first time, and from the determination of the active, the present invention is meaningful Think of things. Also in extract administration of the maitake, similar clinical test results have been obtained.
【0024】[0024]
【発明の効果】本発明は上述のようにしたから、本発明
に係る物質を使用することで、HIV陽性患者の免疫力
の回復が達成され、その結果としてHIV感染に伴うA
IDS関連症候症状の軽減も可能となる。As described above, the present invention has been described above. Thus, by using the substance according to the present invention, the immunity of HIV-positive patients can be restored, and as a result, A associated with HIV infection can be recovered.
It is also possible to reduce IDS-related symptoms and symptoms.
フロントページの続き (56)参考文献 特開 平4−66536(JP,A) 特開 平2−286623(JP,A) 特開 平2−134325(JP,A) 特開 平4−308531(JP,A) 特開 平1−312980(JP,A) 特開 平2−211848(JP,A) 特開 平5−336918(JP,A) 難波宏彰,「マイタケの不思議パワ ー」、KKベストセラーズ、1992年10月 5日初版発行、第138〜141頁 川合正充,「きのこの利用」、築地書 館株式会社、1988年12月15日初版発行、 第83〜87頁 水野卓,「キノコの化学・生化学」株 式会社学会出版センター、1992年1月15 日、第237〜244頁Continuation of the front page (56) References JP-A-4-66536 (JP, A) JP-A-2-286623 (JP, A) JP-A-2-134325 (JP, A) JP-A-4-308531 (JP) JP-A-1-312980 (JP, A) JP-A-2-211848 (JP, A) JP-A-5-336918 (JP, A) Hiroaki Namba, "Mysterious Power of Maitake", KK Bestsellers , October 5, 1992, First Edition, pp. 138-141, Masamitsu Kawai, "Use of Mushrooms", Tsukiji Shokan Co., Ltd., First Edition, December 15, 1988, pp. 83-87, Taku Mizuno, "Mushroom Chemistry and Biochemistry, Inc. Publishing Center, January 15, 1992, pp. 237-244
Claims (2)
少抑制若しくは増加剤であって、マイタケの子実体若し
くは培養菌糸体を乾燥し、該乾燥物を粉末化して成る、
投与量が成人1日当たり3乃至10gであることを特徴
とするAIDSにおけるヘルパーT細胞数の減少抑制若
しくは増加剤。1. An agent for suppressing or increasing the number of helper T cells in AIDS, comprising drying a fruit body or a cultured mycelium of Maitake, and powdering the dried product.
An agent for suppressing or increasing the number of helper T cells in AIDS, wherein the dose is 3 to 10 g per adult per day.
少抑制若しくは増加剤であって、マイタケの子実体若し
くは培養菌糸体を乾燥し、該乾燥物を粉末化して成る、
投与量が成人1日当たり3gであることを特徴とするA
IDSにおけるヘルパーT細胞数の減少抑制若しくは増
加剤。2. An agent for suppressing or increasing the number of helper T cells in AIDS, comprising drying a fruit body or a cultured mycelium of Maitake and powdering the dried product.
A characterized in that the dosage is 3 g per adult per day
An agent for suppressing or increasing the number of helper T cells in IDS.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5218908A JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5218908A JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP29334698A Division JP3195916B2 (en) | 1993-09-02 | 1998-10-15 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH0769913A JPH0769913A (en) | 1995-03-14 |
JP2905911B2 true JP2905911B2 (en) | 1999-06-14 |
Family
ID=16727205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5218908A Expired - Lifetime JP2905911B2 (en) | 1993-09-02 | 1993-09-02 | Agent for suppressing or increasing the number of helper T cells in AIDS |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2905911B2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2859843B2 (en) * | 1996-03-08 | 1999-02-24 | 株式会社雪国まいたけ | Antitumor substance extracted from Maitake |
JP4842507B2 (en) * | 2003-11-19 | 2011-12-21 | 株式会社雪国まいたけ | Anti-influenza virus activator |
JP2008106018A (en) | 2006-10-27 | 2008-05-08 | Yukiguni Maitake Co Ltd | Substance having anti-influenza virus activity derived from grifola frondosa and its manufacturing method |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01312980A (en) * | 1988-06-10 | 1989-12-18 | Noda Shiyokukin Kogyo Kk | Production of healthy food |
JPH02211848A (en) * | 1989-02-10 | 1990-08-23 | Iwade Kingaku Kenkyusho:Kk | Functional food containing protein polysaccharide component of agaricus blazei |
-
1993
- 1993-09-02 JP JP5218908A patent/JP2905911B2/en not_active Expired - Lifetime
Non-Patent Citations (3)
Title |
---|
川合正充,「きのこの利用」、築地書館株式会社、1988年12月15日初版発行、第83〜87頁 |
水野卓,「キノコの化学・生化学」株式会社学会出版センター、1992年1月15日、第237〜244頁 |
難波宏彰,「マイタケの不思議パワー」、KKベストセラーズ、1992年10月5日初版発行、第138〜141頁 |
Also Published As
Publication number | Publication date |
---|---|
JPH0769913A (en) | 1995-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6468542B2 (en) | Germination activated Ganoderma lucidum spores and method for producing the same | |
JP2905911B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
US2935448A (en) | Phosphatide therapeutic composition and method of treatment therewith | |
US6746675B2 (en) | Physiologically active compositions based upon active ingredients of Basidiomycotina and Araliaceae | |
JP3195916B2 (en) | Agent for suppressing or increasing the number of helper T cells in AIDS | |
US6893641B2 (en) | Ganoderma lucidum spores for treatment of autoimmune diseases | |
US8609160B2 (en) | Composition and method of treating lipid encapsulated virus infections | |
JPH02134325A (en) | Remedy for aids and production thereof | |
KR101266527B1 (en) | Composition for inhibition of trasplant rejection containing the cordyceps mycellia extract as an active ingredient | |
GB2359562A (en) | T cell immunoactivity potentiators containing shiit ake mushroom hypha extract | |
JPH0925237A (en) | Therapeutic agent for viral disease containing cordyceps sinensis sacc. | |
JPH06199674A (en) | Medicine related to treatment and prevention for opportunistic infectious disease | |
JPH02503314A (en) | Treatment agent for human dyslipidemia | |
Duke | Effect of trichlorophone against West African forest strain of Onchocerca volvulus | |
CA2168263A1 (en) | Pharmaceutical compositions | |
EP0631785A1 (en) | Mineral ion solution, anti-human immunodeficiency virus agent, and aids-treating agent | |
WO2008064411A1 (en) | Nutritional supplement | |
JPH07215852A (en) | Immunosuppressant | |
JP2001163797A (en) | Hepatitis protective agent | |
JPS63208533A (en) | Crude drug raw material having medicinal effect on aids | |
JPS60192554A (en) | Method of removing bitterness from essence | |
EP0765662A1 (en) | Hiv growth inhibitory composition | |
JPH06128288A (en) | Polypeptide and medicinal composition for treatment of viral infection containing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110402 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120402 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130402 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140402 Year of fee payment: 15 |